The short version of MC4 receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-11. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
The US Air Force had been developing a program to launch the first man in space, named Man in Space Soonest. This program studied several different types of one-man space vehicles, settling on a ballistic re-entry capsule launched on a derivative Atlas missile, and selecting a group of nine candidate pilots. After NASA's creation, the program was transferred over to the civilian agency's Space Task Group and renamed Project Mercury on November 26, 1958. The Mercury spacecraft was designed by the STG's chief engineer Maxime Faget. NASA selected a new group of astronaut (from the Greek for "star sailor") candidates from Navy, Air Force and Marine test pilots, and narrowed this down to a group of seven for the program. Capsule design and astronaut training began immediately, working toward preliminary suborbital flights on the Redstone missile, followed by orbital flights on the Atlas. Each flight series would first start unpiloted, then carry a non-human primate, then finally humans. The Mercury spacecraft's principal designer was Maxime Faget, who started research for human spaceflight during the time of the NACA. It consisted of a conical capsule with a cylindrical pack of three solid-fuel retro-rockets strapped over a beryllium or fiberglass heat shield on the blunt end. Base diameter at the blunt end was 6.0 feet (1.8 m) and length was 10.8 feet (3.3 m); with the launch escape system added, the overall length was 25.9 feet (7.9 m). With 100 cubic feet (2.8 m3) of habitable volume, the capsule was just large enough for a single astronaut.
The attraction between the charged metal and water ions will rapidly increase the surface area, causing an exponential increase of ionisation. When the repulsive forces within the liquid metal surface exceeds the forces of the surface tension, it vigorously explodes. The hydroxides themselves are the most basic hydroxides known, reacting with acids to give salts and with alcohols to give oligomeric alkoxides. They easily react with carbon dioxide to form carbonates or bicarbonates, or with hydrogen sulfide to form sulfides or bisulfides, and may be used to separate thiols from petroleum. They react with amphoteric oxides: for example, the oxides of aluminium, zinc, tin, and lead react with the alkali metal hydroxides to give aluminates, zincates, stannates, and plumbates. Silicon dioxide is acidic, and thus the alkali metal hydroxides can also attack silicate glass.
==== Lamarckian inheritance ==== Similarly, his experiments with Wilfred Eade Agar to test William McDougall's supposed demonstration of Lamarckian inheritance of training in rats were negative and showed the inadequacy of McDougall's controls, the first results being published in 1935.
Sources: en.wikipedia.org
There are about 18,000 U.S. police agencies from local to national level in the United States. Law in the United States is mainly enforced by local police departments and sheriff departments in their municipal or county jurisdictions. The state police departments have authority in their respective state, and federal agencies such as the Federal Bureau of Investigation (FBI) and the U.S. Marshals Service have national jurisdiction and specialized duties, such as protecting civil rights, national security, enforcing U.S. federal courts' rulings and federal laws, and interstate criminal activity. State courts conduct almost all civil and criminal trials, while federal courts adjudicate the much smaller number of civil and criminal cases that relate to federal law. There is no unified "criminal justice system" in the United States. The American prison system is largely heterogenous, with thousands of relatively independent systems operating across federal, state, local, and tribal levels. In 2026, "these systems hold nearly 2 million people in 1,566 state prisons, 98 federal prisons, 3,116 local jails, 1,277 juvenile correctional facilities, 220 immigration detention facilities, and 77 Indian country jails, as well as in military prisons, civil commitment centers, state psychiatric hospitals, and prisons in the U.S. territories—at a system-wide cost of at least $445 billion each year." Despite disparate systems of confinement, four main institutions dominate: federal prisons, state prisons, local jails, and juvenile correctional facilities.
== Medical technology == Medical technology, or "medtech", encompasses a wide range of healthcare products and is used to treat diseases and medical conditions affecting humans. Such technologies are intended to improve the quality of healthcare delivered through earlier diagnosis, less invasive treatment options and reduction in hospital stays and rehabilitation times. Recent advances in medical technology have also focused on cost reduction. Medical technology may broadly include medical devices, information technology, biotech, and healthcare services. The impacts of medical technology involve social and ethical issues. For example, physicians can seek objective information from technology rather than read subjective patient reports. A major driver of the sector's growth is the consumerization of medtech. Supported by the widespread availability of smartphones and tablets, providers can reach a large audience at low cost, a trend that stands to be consolidated as wearable technologies spread throughout the market. In the years 2010–2015, venture funding has grown 200%, allowing US$11.7 billion to flow into health tech businesses from over 30,000 investors in the space.
If a compound containing more than two kinds of building blocks is synthesised, a step is added before the deprotection of the building block bound to the bead; a functional group which is on the bead and did not react with an added building block has to be protected by another protecting group which is not removed at the deprotective condition of the building block. Byproducts which lack the building block of this step only are prevented by this step. In addition, this step makes it easy to purify the synthesised compound after cleavage from the bead.
Sources: en.wikipedia.org
== Associated conditions == The increase in obesity prevalence has occurred alongside rising rates of diabetes and other metabolic disorders. According to Vigitel, the prevalence of self-reported medical diagnosis of diabetes increased from 5.5% in 2006 to 12.9% in 2024. The trend closely parallels the increase in obesity prevalence observed during the same period. Obesity is associated with a wide range of chronic diseases in Brazil, including type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, osteoarthritis, and several forms of cancer. The Brazilian Association for the Study of Obesity and Metabolic Syndrome and international clinical guidelines recognise obesity as a chronic, relapsing, multifactorial disease requiring long-term management. The Organisation for Economic Co-operation and Development has identified obesity as one of the most important modifiable risk factors affecting population health in Brazil.
A tablet of micronized progesterone which is marketed under the brand name Luteina is indicated for sublingual administration in addition to vaginal administration and is available in Poland and Ukraine. A progesterone suppository which is marketed under the brand name Cyclogest is indicated for rectal administration in addition to vaginal administration and is available in Cyprus, Hong Kong, India, Malaysia, Malta, Oman, Singapore, South Africa, Thailand, Tunisia, Turkey, the United Kingdom, and Vietnam. An aqueous solution of progesterone complexed with β-cyclodextrin for subcutaneous injection is marketed under the brand name Prolutex in the Czech Republic, Hungary, Italy, Poland, Portugal, Slovakia, Spain, and Switzerland. A non-systemic topical gel formulation of progesterone for local application to the breasts to treat breast pain is marketed under the brand name Progestogel and is available in Belgium, Bulgaria, Colombia, Ecuador, France, Georgia, Germany, Hong Kong, Lebanon, Peru, Romania, Russia, Serbia, Switzerland, Tunisia, Venezuela, and Vietnam. It was also formerly available in Italy, Portugal, and Spain, but was discontinued in these countries. A progesterone intrauterine device was previously marketed under the brand name Progestasert and was available in Canada, France, the United States, and possibly other countries, but was discontinued. Progesterone vaginal rings are marketed under the brand names Fertiring and Progering and are available in Chile, Ecuador, and Peru.
Scalephobicity and antifouling Coatings for gas evolution reaction electrodes for efficient bubble detachment Breast implants Contact lenses (silicone hydrogels, polyacrylamides, polymacon) Water sustainability: Hydrogels have emerged as promising materials platforms for solar-powered water purification, water disinfection, and atmospheric water generator. Disposable diapers where they absorb urine, or in sanitary napkins Dressings for healing of burn or other hard-to-heal wounds. Wound gels are excellent for helping to create or maintain a moist environment. EEG and ECG medical electrodes using hydrogels composed of cross-linked polymers (polyethylene oxide, polyAMPS and polyvinylpyrrolidone) Encapsulation of quantum dots Environmentally sensitive hydrogels (also known as 'smart gels' or 'intelligent gels'). These hydrogels have the ability to sense changes of pH, temperature, or the concentration of metabolite and release their load as result of such a change. Fibers Glue Granules for holding soil moisture in arid areas Air bubble-repellent (superaerophobicity). Can improve the performance and stability of electrodes for water electrolysis. Culturing cells: Hydrogel-coated wells have been used for cell culture. Biosensors: Hydrogels that are responsive to specific molecules, such as glucose or antigens, can be used as biosensors, as well as in DDS. Cell carrier: Injectable hydrogels can be used to carry drugs or cells for applications in tissue regeneration or 3D bioprinting.
Aminorex Amphetamine Benzylpiperazine Cathinone Ephedrine Lisdexamfetamine Mephedrone Methamphetamine Methylenedioxymethamphetamine (MDMA) Methylone Octopamine Phenethylamine Phenmetrazine Phentermine Phenylpropanolamine Pseudoephedrine Tyramine
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.